1,721,197 research outputs found
Adjuvant chemotherapy of gastric cancer: which regimen?
No full textGastric cancer is still a major health problem and a leading cause of cancer mortality despite a
worldwide decline in incidence. Surgical resection with curative potential is the only treatment
modality of scientific proven effectiveness. Many phase III trials of adjuvant therapy have been conducted,
however, postoperative treatment modalities have not proven to be superior to pos-surgical
observation alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an
investigational approach. Improved clinical trial designs with standardized surgical techniques and
the incorporation of newer active drugs are needed
Novel investigational drugs for gastric cancer
No full textBACKGROUND: Gastric cancer still represents a leading cause of death worldwide. Several cytotoxic agents have demonstrated activity and combination regimens improve progression-free survival, overall survival and quality of life. Nevertheless, now there is no standard therapy for advanced gastric cancer patients.
OBJECTIVE: To evaluate the role of new investigational agents.
METHODS: We analysed Phase I, II and III studies that evaluated tailored drugs directed against the epidermal growth factor receptor (EGFR), the c-erbB2, the vascular endothelial growth factor (VEGF), the vascular endothelial growth factor receptor (VEGFR), the matrix metalloproteinases (MMP) and the mammalian target of rapamycin (mTOR).
CONCLUSION: Data from Phase II trials indicate the potential of improved efficacy of chemotherapy when administered in combination with bevacizumab and cetuximab. Trastuzumab results are ongoing, while marimastat has not obtained clinical developments even if it has demonstrated to be an active drug in this setting of patients
- …
